Genelux (GNLX) and Newsoara BioPharma said Tuesday that preliminary data from their co-sponsored ongoing phase 1b/2 small-cell lung cancer study indicated anti-tumor effect from Olvi-Vec immunochemotherapy.
In the initial dose escalation groups, five of the seven evaluable participants for anti-tumor response achieved disease control as the best response, with two of those five exhibiting a partial response, the companies said.
Those five also showed reductions in all of their individual target lesions, according to the companies.
The companies added that Olvi-Vec was "generally well-tolerated with a favorable safety profile."
They said enrollment into dose escalation groups continues to evaluate safety and the recommended intravenous dose for the phase 2 trial of Olvi-Vec, which they said is Genelux's most advanced product candidate.
Price: 3.46, Change: -0.43, Percent Change: -11.05
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.